Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 62.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 57.20% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Prostalund AB was 68.40% per year. The lowest was -165.00% per year. And the median was 20.75% per year.
Prostalund AB (FRA:7PL0) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Prostalund AB 3-Year EBITDA Growth Rate Related Terms
FRA:7PL0 vs HCA, THC, UHS: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Prostalund AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostalund AB 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Prostalund AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Prostalund AB's 3-Year EBITDA Growth Rate falls into.
Prostalund AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 62.80% mean?
Prostalund AB (FRA:7PL0) has a 3-Year EBITDA Growth Rate of 62.80% as of Sep. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prostalund AB and its competitors. This is 203% above median its historical median of 20.75.
Is Prostalund AB's 3-Year EBITDA Growth Rate too high?
Prostalund AB's current 3-Year EBITDA Growth Rate of 62.80% is 203% above median its 10-year median of 20.75. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Prostalund AB's value of 62.80% is 515.7% above this industry median. Overall, Prostalund AB has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Prostalund AB's 3-Year EBITDA Growth Rate compare to HCA and THC?
Prostalund AB's 3-Year EBITDA Growth Rate of 62.80% can be compared against companies in the Healthcare Providers & Services industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Prostalund AB's value of 62.80% is 515.7% above this benchmark. While the company's 10-year median is 20.75 vs. the industry median of 10.20, Prostalund AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 526 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostalund AB's current 3-Year EBITDA Growth Rate of 62.80% is 515.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Prostalund AB and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostalund AB's current 3-Year EBITDA Growth Rate is 62.80%, which is 203% above median its own 10-year median of 20.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostalund AB stock overvalued right now?
Prostalund AB (FRA:7PL0) has a current 3-Year EBITDA Growth Rate of 62.80%. The stock's GF Value™ is €0.02, compared to a current price of €0.00 — trading 97.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 62.80%, which is 203% above median its 10-year median of 20.75 and 515.7% above the Healthcare Providers & Services industry median of 10.20. Prostalund AB's overall GF Score™ is 10/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Prostalund AB (FRA:7PL0), the current 3-Year EBITDA Growth Rate is 62.80% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostalund AB (FRA:7PL0) Overvalued in 2026?
Based on GuruFocus' analysis, Prostalund AB stock appears to be undervalued.
The current stock price of €0.00 is trading 97.5% below its estimated GF Value™ of €0.02.
Key valuation signals for FRA:7PL0:
3-Year EBITDA Growth Rate: 62.80% (203% above median its 10-year median of 20.75)
GF Value™: €0.02 vs. price of €0.00 (97.5% below fair value)
Industry Position: 515.7% above the Healthcare Providers & Services median
No single metric tells the full story. See the FRA:7PL0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostalund AB develops, markets and sells urological products. The Company has a treatment concept (CoreTherm Concept) for personalized heat treatment for the condition benign prostatic hyperplasia, also known as BPH or BPE, which mainly affects men over the age of 50. It has developed a new platform, CoreTherm Eagle which includes an inbuilt computer, real-time temperature reading, patient data storage and inbuilt recommendations for treating physicians.
10GF Score
Get the complete analysis for FRA:7PL0
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7PL0 has been successfully added to your 
